379 related articles for article (PubMed ID: 33359740)
1. Metabolic remodeling of dystrophic skeletal muscle reveals biological roles for dystrophin and utrophin in adaptation and plasticity.
Hardee JP; Martins KJB; Miotto PM; Ryall JG; Gehrig SM; Reljic B; Naim T; Chung JD; Trieu J; Swiderski K; Philp AM; Philp A; Watt MJ; Stroud DA; Koopman R; Steinberg GR; Lynch GS
Mol Metab; 2021 Mar; 45():101157. PubMed ID: 33359740
[TBL] [Abstract][Full Text] [Related]
2. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
[TBL] [Abstract][Full Text] [Related]
3. Utrophin influences mitochondrial pathology and oxidative stress in dystrophic muscle.
Kennedy TL; Moir L; Hemming S; Edwards B; Squire S; Davies K; Guiraud S
Skelet Muscle; 2017 Oct; 7(1):22. PubMed ID: 29065908
[TBL] [Abstract][Full Text] [Related]
4. Increasing muscle contractility through low-frequency stimulation alters tibial bone geometry and reduces bone strength in
Chan AS; Hardee JP; Blank M; Cho EH; McGregor NE; Sims NA; Lynch GS
J Appl Physiol (1985); 2023 Jul; 135(1):77-87. PubMed ID: 37262103
[TBL] [Abstract][Full Text] [Related]
5. Embryonic myosin is a regeneration marker to monitor utrophin-based therapies for DMD.
Guiraud S; Edwards B; Squire SE; Moir L; Berg A; Babbs A; Ramadan N; Wood MJ; Davies KE
Hum Mol Genet; 2019 Jan; 28(2):307-319. PubMed ID: 30304405
[TBL] [Abstract][Full Text] [Related]
6. Analysis of gene expression differences between utrophin/dystrophin-deficient vs mdx skeletal muscles reveals a specific upregulation of slow muscle genes in limb muscles.
Baker PE; Kearney JA; Gong B; Merriam AP; Kuhn DE; Porter JD; Rafael-Fortney JA
Neurogenetics; 2006 May; 7(2):81-91. PubMed ID: 16525850
[TBL] [Abstract][Full Text] [Related]
7. Novel adeno-associated viral vector delivering the utrophin gene regulator jazz counteracts dystrophic pathology in mdx mice.
Strimpakos G; Corbi N; Pisani C; Di Certo MG; Onori A; Luvisetto S; Severini C; Gabanella F; Monaco L; Mattei E; Passananti C
J Cell Physiol; 2014 Sep; 229(9):1283-91. PubMed ID: 24469912
[TBL] [Abstract][Full Text] [Related]
8. BGP-15 Improves Aspects of the Dystrophic Pathology in mdx and dko Mice with Differing Efficacies in Heart and Skeletal Muscle.
Kennedy TL; Swiderski K; Murphy KT; Gehrig SM; Curl CL; Chandramouli C; Febbraio MA; Delbridge LM; Koopman R; Lynch GS
Am J Pathol; 2016 Dec; 186(12):3246-3260. PubMed ID: 27750047
[TBL] [Abstract][Full Text] [Related]
9. Celecoxib treatment improves muscle function in mdx mice and increases utrophin A expression.
Péladeau C; Adam NJ; Jasmin BJ
FASEB J; 2018 Sep; 32(9):5090-5103. PubMed ID: 29723037
[TBL] [Abstract][Full Text] [Related]
10. Muscle structure influences utrophin expression in mdx mice.
Banks GB; Combs AC; Odom GL; Bloch RJ; Chamberlain JS
PLoS Genet; 2014 Jun; 10(6):e1004431. PubMed ID: 24922526
[TBL] [Abstract][Full Text] [Related]
11. Alternative utrophin mRNAs contribute to phenotypic differences between dystrophin-deficient mice and Duchenne muscular dystrophy.
Perkins KJ; Davies KE
FEBS Lett; 2018 Jun; 592(11):1856-1869. PubMed ID: 29772070
[TBL] [Abstract][Full Text] [Related]
12. Identification of FHL1 as a therapeutic target for Duchenne muscular dystrophy.
D'Arcy CE; Feeney SJ; McLean CA; Gehrig SM; Lynch GS; Smith JE; Cowling BS; Mitchell CA; McGrath MJ
Hum Mol Genet; 2014 Feb; 23(3):618-36. PubMed ID: 24087791
[TBL] [Abstract][Full Text] [Related]
13. Muscle specific kinase protects dystrophic mdx mouse muscles from eccentric contraction-induced loss of force-producing capacity.
Trajanovska S; Ban J; Huang J; Gregorevic P; Morsch M; Allen DG; Phillips WD
J Physiol; 2019 Sep; 597(18):4831-4850. PubMed ID: 31340406
[TBL] [Abstract][Full Text] [Related]
14. Restoration of all dystrophin protein interactions by functional domains in trans does not rescue dystrophy.
Gardner KL; Kearney JA; Edwards JD; Rafael-Fortney JA
Gene Ther; 2006 May; 13(9):744-51. PubMed ID: 16307000
[TBL] [Abstract][Full Text] [Related]
15. Activation of non-myogenic mesenchymal stem cells during the disease progression in dystrophic dystrophin/utrophin knockout mice.
Sohn J; Lu A; Tang Y; Wang B; Huard J
Hum Mol Genet; 2015 Jul; 24(13):3814-29. PubMed ID: 25859011
[TBL] [Abstract][Full Text] [Related]
16. Striated muscle activator of Rho signalling (STARS) overexpression in the mdx mouse enhances muscle functional capacity and regulates the actin cytoskeleton and oxidative phosphorylation pathways.
Sadler KJ; Gatta PAD; Naim T; Wallace MA; Lee A; Zaw T; Lindsay A; Chung RS; Bello L; Pegoraro E; Lamon S; Lynch GS; Russell AP
Exp Physiol; 2021 Jul; 106(7):1597-1611. PubMed ID: 33963617
[TBL] [Abstract][Full Text] [Related]
17. Second-generation compound for the modulation of utrophin in the therapy of DMD.
Guiraud S; Squire SE; Edwards B; Chen H; Burns DT; Shah N; Babbs A; Davies SG; Wynne GM; Russell AJ; Elsey D; Wilson FX; Tinsley JM; Davies KE
Hum Mol Genet; 2015 Aug; 24(15):4212-24. PubMed ID: 25935002
[TBL] [Abstract][Full Text] [Related]
18. Sub-physiological sarcoglycan expression contributes to compensatory muscle protection in mdx mice.
Li D; Long C; Yue Y; Duan D
Hum Mol Genet; 2009 Apr; 18(7):1209-20. PubMed ID: 19131360
[TBL] [Abstract][Full Text] [Related]
19. Exercise increases utrophin protein expression in the mdx mouse model of Duchenne muscular dystrophy.
Gordon BS; Lowe DA; Kostek MC
Muscle Nerve; 2014 Jun; 49(6):915-8. PubMed ID: 24375286
[TBL] [Abstract][Full Text] [Related]
20. The potential of utrophin and dystrophin combination therapies for Duchenne muscular dystrophy.
Guiraud S; Edwards B; Babbs A; Squire SE; Berg A; Moir L; Wood MJ; Davies KE
Hum Mol Genet; 2019 Jul; 28(13):2189-2200. PubMed ID: 30990876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
